Sbi Securities Co., Ltd. Apellis Pharmaceuticals, Inc. Transaction History
Sbi Securities Co., Ltd.
- $3.48 Trillion
- Q2 2025
A detailed history of Sbi Securities Co., Ltd. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Sbi Securities Co., Ltd. holds 91 shares of APLS stock, worth $2,197. This represents 0.0% of its overall portfolio holdings.
Number of Shares
91
Previous 89
2.25%
Holding current value
$2,197
Previous $1.95 Million
19.06%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding APLS
# of Institutions
297Shares Held
132MCall Options Held
2.97MPut Options Held
623K-
Avoro Capital Advisors LLC New York, NY12.2MShares$295 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$287 Million17.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$245 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.75MShares$236 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.98MShares$217 Million0.03% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.65B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...